REQUEST **FOR**

CONTINUED EXAMINATION (RCE) **TRANSMITTAL**

Subsection (b) of 35 USC §132, effective on May 29. 2000, provides for continued examination of an utility or plant application filed on or after June 8. 1995. See The American inventors Protection Act of 1999 (AIPA).

Application Number	09/674,800
Filing Date	November 06, 2000
First Named Inventor	Thomas STRÜNGMANN
Group Art Unit	1615
Examiner Name	Tran, Susan T.
Attorney Docket Number	4271-29RCE

This is a Request for Continued Examination (RCE) under 37 C.F.R. § 1.114 of the above-identified application. 37 C.F.R. § 1.114 is effective on May 29, 2000. If the above-identified application was filed prior to May 29, 2000 applicant may wish to consider filing a continued prosecution application (CPA) under 37 C.F.R. § 1.53(d) (PTO/SB/29) instead of a RCE to be eligible for the patent term adjustment provisions of the AIPA. See Changes to Application Examination and Provisional Application Practice, Interim Rule, 65 Fed. Reg. 14865 (Mar. 20, 2000), 1233 Off. Gaz. Pat. Office 47 (April 11, 2000), which established RCE practice.

1. Submission required under 37 C.F.R. § 1.114

- a. [] Previously submitted

 - ii. ∏
 - iii.∏
- b. [x] Enclosed
 - i. [x] Amendment/Reply
 - ii. ∏
 - iii.∏
 - iv.∏

Miscellaneous 2.

- Suspension of action of the above-identified application is requested under 37 C.F.R. § 1.103(c) for a period of months. (Period of suspension shall not exceed three months; Fee under 37 C.F.R. § 1.17(I) required)
- Other b. []_

Fees


3.

The RCE fee under 37 C.F.R. 1.17(e) is required by 37 C.F.R. 1.114 when the RCE is filed.

- a. [x] The Director is hereby authorized to charge the following fees, or credit any overpayments, to Deposit Account No.: 03-2412.
 - i. [x] RCE fee required under 37 C.F.R.§ 1.17(e)
 - Extension of time fee (37C.F.R. §§ 1.136 and 1.17)
 - Small Entity Status is being claimed for this application. iii.[]
 - vi.[] Other
- b. [x] Check in the amount of \$770.00 enclosed.
- Payment by credit card (Form PTO-2038 enclosed)

S	IGNATURE OF A	PPLICANT, AT	TORNEY, C	R AGENT REQU	IRED	2	0.0
Name (Print/Type)	Howard R. Jaeger		Registration	Registration No. (Attorney/Agent) 31,376			7
Signature	Howard R.	Jacaen	Date December 31, 2003		, 2003	0967	
			•			8	
CERTIFICATE OF MAILING OR TRANSMISSION						000	
I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner For Patents, Mail Stop RCE, P.O. Box 1450, Alexandria, VA 22313-1450, or facsimile transmitted to the U.S. Patent and Trademark Office on: December 31, 2003						CNSUYEN 00	
Name (Print/Type)	Howard R. Jaeger	^		· ·		3	
Signature	Howard R.	Jalger	Date	December 31	, 2003	2004	1801
		V				55/	٤





FILING FEE COMPUTATION SHEET

Submit an original and a duplicate for fee processing

Dated: December 31, 2003

Mail Stop RCE Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

In re RCE Application of: Thomas STRÜNGMANN

For: Transdermal Therapeutic System for the Administration of

Candesartan

Parent Serial No.: 09/674,800

CEST AVAILABLE COPY

The filing fee has been calculated as shown below:

FOR:	Col. 1	Col. 2	SMALL ENTITY		OTHER THAN SMALL ENTITY	
	# FILED	# EXTRA				
BASIC FEE				\$385		\$770
TOTAL CLAIMS	<u>19</u> - 20 =	0	x 9 =	\$	x 18 =	\$
INDEPENDENT CLAIMS	<u>2</u> - 3 =	<u>0</u>	x 43 =	\$	x 86 =	\$
[] MULTIPLE DEPENDENCY			+\$145 =	\$	+290	\$
* If the difference in Col. 1 is less than zero, enter "0" in Col. 2			TOTAL:	\$		\$ 770

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re RCE Application of

Thomas STRÜNGMANN

Parent Serial No.:

09/674,800

Parent Filed:

November 06, 2000

For:

Transdermal Therapeutic System

for the Administration of

Candesartan

Check box if applicable:

DUPLICATE

GENERAL AUTHORIZATION FOR PAYMENT OF FEES AND PETITIONS FOR EXTENSIONS OF TIME

Submit an original and a duplicate for fee processing

Mail Stop RCE Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

PEST AVAILABLE COPY

Sir:

The Commissioner is hereby authorized to credit overpayments or charge the following fees to Deposit Account No. 03-2412

- [X] Any filing fees required under 37 CFR §1.16.
- [X] Any patent application processing fees under 37 CFR §1.17 not otherwise paid by check.
- The issue fee set in 37 CFR 1.18 at 3 months from mailing of the Notice of Allowance, pursuant to 37 CFR 1.311 (b) provided the fee has not already been paid by check.
- [X] Any filing fees under 37 CFR 1.16 for presentation of extra claims.

Respectfully submitted,

COHEN, PONTANI, LIEBERMAN & PAVANE

By

Howard R. Jaeger


Reg. No. 31,376

551 Fifth Avenue, Suite 1210

New York, New York 10176

(212) 687-2770

Dated: December 31, 2003



Patent

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of

Thomas STRÜNGMANN et al.

Serial No.:

09/674,800

Filed: concurrently as 37 C.F.R. 1.114 RCE Application

For:

Transdermal Therapeutic

System

for

Administration of Candesartan

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450



PRELIMINARY AMENDMENT

SIR:

Prior to examination of the above-identified application, amend the application as follows:

Amendments to the Claims are reflected in the listing of claims which begins on page 2 of this paper.

Remarks/Arguments begin on page 9 of this paper.